Xenon Pharmaceuticals Inc (XENE) — Cash Flow-to-Debt Ratio
Xenon Pharmaceuticals Inc (XENE) has a Cash Flow-to-Debt Ratio of -0.20x as of December 2025, meaning its operating cash flow of $-81.48 Million could theoretically repay 0% of its total liabilities ($399.91 Million) in one year. Explore Xenon Pharmaceuticals Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Xenon Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Xenon Pharmaceuticals Inc across 14 annual periods. Also explore XENE total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Xenon Pharmaceuticals Inc (2012–2025)
Year-by-year debt coverage analysis for Xenon Pharmaceuticals Inc. For market capitalisation and broader financial context, see Xenon Pharmaceuticals Inc (XENE) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.70x | $-279.12 Million | $399.91 Million | ▲ +83.4% |
| 2024 | -4.20x | $-181.39 Million | $43.24 Million | ▼ -6.5% |
| 2023 | -3.94x | $-145.33 Million | $36.88 Million | ▼ -30.7% |
| 2022 | -3.01x | $-98.43 Million | $32.65 Million | ▲ +4.7% |
| 2021 | -3.16x | $-69.50 Million | $21.97 Million | ▼ -17.2% |
| 2020 | -2.70x | $-48.12 Million | $17.83 Million | ▼ -3146.6% |
| 2019 | -0.08x | $-4.63 Million | $55.72 Million | ▲ +95.4% |
| 2018 | -1.81x | $-34.72 Million | $19.13 Million | ▲ +35.6% |
| 2017 | -2.82x | $-28.73 Million | $10.19 Million | ▲ +48.3% |
| 2016 | -5.46x | $-19.57 Million | $3.59 Million | ▲ +12.1% |
| 2015 | -6.21x | $-18.10 Million | $2.92 Million | ▼ -34277.6% |
| 2014 | 0.02x | $266.00K | $14.64 Million | ▲ +116.6% |
| 2013 | -0.11x | $-3.32 Million | $30.37 Million | ▼ -112.2% |
| 2012 | 0.90x | $45.57 Million | $50.68 Million | — |